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Abstract 
Introduction: Neuropathic pain can be very difficult to treat and it is one of the important medical challenging 
about pain treatments. Muscimol as a new agonist of gamma-Aminobutyric acid receptor type A (GABAA) have 
been introduced for pain management. Thus, the present study was performed to evaluate the pain alleviating 
effect of intrathecal injection of different doses of muscimol as GABAA receptor agonist in spinal cord injury (SCI) 
model of neuropathic pain. Methods: In the present experimental study, male Wistar rats were treated by mus-
cimol 0.01, 0.1 or 1 µg/10ul, intrathecally (i.t.) three weeks after induction of spinal cord injury using compres-
sion injury model. Neuropathic pain symptoms were assessed at before treatment, 15 minutes, one hour and 
three hours after muscimol administration. The time of peak effect and optimum dosage was assessed by repeat-
ed measures analysis of variance and analysis of covariance, respectively. Results: Muscimol with the dose of 
0.01 µg in 15 minutes caused to improve the thermal hyperalgesia (df: 24, 5; F= 6.6; p<0.001), mechanical hyper-
algesia (df: 24, 5; F= 7.8; p<0.001), cold allodynia (df: 24, 5; F= 6.96; p<0.001), and mechanical allodynia (df: 24, 5; 
F= 15.7; p<0.001). The effect of doses of 0.1 µg and 1 µg were also significant. In addition, the efficacy of different 
doses of muscimol did not have difference on thermal hyperalgesia (df: 24, 5; F= 1.52; p= 0.24), mechanical hy-
peralgesia (df: 24, 5; F= 0.3; p= -0.75), cold allodynia (df: 24, 5; F= 0.8; p= -0.56), and mechanical allodynia (df: 24, 
5; F= 1.75; p= 0.86). Conclusion: The finding of the present study revealed that using muscimol with doses of 
0.01µg, 0.1µg, and 1 µg reduces the symptoms of neuropathic pain. In addition, the effect of GABAA agonist is 
short term and its effectiveness gradually decreases by time. 
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Introduction:1 
oday neuropathic pain, which happens following 
the injury or dysfunction of peripheral or central 
nervous system, turns to one of the important 
medical challenging about pain. In most of these situa-
tions, neuropathic pain involve the at-level of injury but 
gradually extend and can occurred above or below the 
level of injury. These changes lead to decrease life quali-
ty, functional loss and physical dependence, and un-
dermine mental health and social relations (1). The 
most annoying symptoms of these patients are hyperal-
gesia (hypersensitivity to painful stimulus) and allo-
dynia (pain due to a stimulus which does not normally 
aggravate priorities weather in acute or in chronic cas-
es (2). However, eliminating of these symptoms is one 
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of the current treatment strategies have less efficiency 
and lead only to decrease 30-40% of pain in less than 
half of patients (3). Medications in this situation align 
with some problems such as not responding to drugs 
and their side effects. For example, weight gain and 
constipation are common symptoms of patients with 
spinal cord injuries (SCI) treated with tricyclic antide-
pressants (2). Because of drug resistance, using narcotic 
drugs is not acceptable and long-term use of anti-
epileptic drugs, gabapentin, and topiramate has a low 
effectiveness (4-6). In patients with SCI even narcotic 
drugs, which are one of the best sedative agents, have a 
poor or moderate responses (6). Alternatively, in-
trathecal (i.t) pumps are one of the new common cures 
(7, 8). Intrathecal baclofen has remarkable effects on 
reducing the symptoms of SCI-related pain due. But 
applying this medication in some patients causes to 
worsen the neuropathic pain symptoms (9). Intrathecal 
clonidine has also been suggested in some studies (8). 
T 
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Epidural and intrathecal use of sedative drugs has been 
widely applied and there are strong evidences for their 
helpfulness in acute and chronic situation. Most trials 
and a meta-analysis have shown that preoperative, in-
traoperative and postoperative epidural anaesthesia 
/analgesia reduces the incidence of phantom pain sig-
nificantly (10, 11). Opioids, local anesthetics, alha2- 
agonists, and baclofen are the most significant drugs of 
this group. Along with these agents, newest drug com-
pounds like sodium channel blockers, trophic factors, 
and new agonist of gamma-Aminobutyric acid (GABA) 
receptors have also been introduced (12-14). One of the 
type A of GABA (GABAA) receptor agonists is muscimol 
which is extracted as a psychotropic drug from a mush-
room named Amanita muscaria and used as a local an-
esthetic drug (15, 16). Efficacy of muscimol on reducing 
the neuropathic pain symptoms has been shown in 
some studies, while in most of them the peripheral 
model of neuropathic pain has been used (15, 17). Since 
the main cause of neuropathic pains is direct injury of 
spinal cord, evaluating the effectiveness of intrathecal 
pumps of muscimol in reducing the neuropathic pain 
arisen from SCI has not yet been cleared. Thus, the pre-
sent study was performed to evaluate the pain alleviat-
ing effect of intrathecal injection of different doses of 
muscimol as GABAA receptor agonist in spinal cord in-
jury (SCI) model of neuropathic pain. 
Methods: 
Study design and setting: 
The present experimental study was conducted in ac-
cordance with guidelines of ethics for the evaluation of 
pain in conscious animals (18) and approved by the 
ethic committee of Iran University of medical sciences, 
Tehran, Iran. The length of trials was kept short as 
much as possible and the number of animals taken to a 
minimum with all efforts made to minimize animal suf-
fering. 
Animals and drugs: 
Thirty male Wistar rats (10 rats in each group) weigh-
ing 140-160 g were used. Animals were maintained 
under controlled laboratory conditions (temperature: 
21 ± 1 C; 12 hour light/dark cycle; 4 rats per cage) and 
had free access to water and food. All tests were per-
formed between 10:00 am and 02:00 pm, in a sound-
proof and air-regulated room. Muscimol (Sigma chemi-
cal company, St, Louis, USA) was dissolved in saline and 
the animals received 0.01, 0.1 or 1 ug/10ul, intrathe-
cally (i.t.). Before muscimol administration and 15 
minutes, one hour and three hours after on, behavioral 
tests were evaluated.  
Animal preparation 
A compression injury model was used to induce SCI. 
This method was previously described by Hama and 
Sagen (19). Briefly, after anesthesia [by a combination 
of ketamine (80 mg/kg) and Xylazin (10 mg/kg)], dor-
sal laminectomy was performed at T6–T8 to expose the 
spinal cord. The lower blade of the micro-vascular clip 
(Harvard Apparatus, MA) was placed on the exposed 
cord with avoidance of damage to the adjacent nerve 
roots. After 60 seconds, the clip was removed, muscles 
sutured shut, and skin closed. Three weeks following 
compression, a PE10 cannula was placed intrathecally 
at L5-L6 level of Spinal cord during deep anesthesia 
based on the method introduced by Xu et al (20). For 
this purpose, a longitudinal skin incision was made over 
L4-L5 location and a 6 cm long PE10 cannula implanted 
into the subarachnoid space and passed 1 cm rostrally.  
Behavioral tests 
A) Mechanical allodynia 
The threshold of mechanical allodynia, as a behavioral 
measure of neuropathic pain, was measured by as-
sessing hind paw sensitivity to innocuous mechanical 
stimulation to third metatarsal bone area of the both 
hind paw.  The 50% paw withdrawal thresholds were 
evaluated with a set of specific Von Frey filaments using 
the up-down paradigm (21). Lifting, shaking, or licking 
the paw and running away were considered as positive 
responses. The 50% paw withdrawal thresholds were 
assessed before and 15 minutes, 1 hour, and three 
hours after muscimol administration. Only robust and 
immediate withdrawal responses including lifting, 
shaking or licking the paw and running away were con-
sidered as positive. 
B) Mechanical hyperalgesia  
Increasing mechanical pressure (48 g/s) was applied to 
the hind paw by the Randall–Selitto mechanical hyper-
algesia test for the assessment of mechanical hyperal-
gesia. It can detect neuropathic pain in both fore paws 
and hind paws (22).  The mechanical force was applied 
to the plantar surface of both hind paws (two trials per 
each paw) until a withdrawal response observed. The 
maximum applied pressure was 1000 g to evade dam-
age. The average score of two trials was used in analy-
sis. 
C) Cold allodynia 
The application of a drop (0.1 ml) of acetone to the cen-
ter of plantar surface of hind paw was performed to 
measure cold allodynia (23). Rats were located on a 
mesh floor cages and acetone pushed to center of plan-
tar surface of hind paw. This test was repeated five 
times per foot (3–5 min between each test) and with-
drawal responses calculated as the percentage response 





D) Heat hyperalgesia 
Responses to noxious heat (Hargreaves method) were 
evaluated using a radiant heat source (24). Animals 
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were placed in a transparent Plexiglas box and allowed 
to adapt within 20 minutes. Time to initiating the ther-
mal stimulation to paw withdrawal response was de-
fined as withdrawal latency. A cut-off time was set at 25 
seconds to prevent tissue damage. Each hind paw was 
tested Three times. Finally, the average of three trials 
was used for statistical analysis. 
Statistical analysis 
Data were entered to SPSS version 20 and expressed as 
Mean ± SEM (standard error of mean). One-way analy-
sis of variance (one-way ANOVA) was used to compare 
the difference among three groups before administra-
tion of muscimol. Repeated measures ANOVA was car-
ried out to change the pain over time among before, 15 
minutes, 60 minutes, and 180 minutes after treatment 
to clear the time of peak effect. For assessment of dos-
age effect, analysis of covariance (ANCOA) adjusted for 
mean pain score before muscimol administration was 
performed. Because the maximum effect was observed 
at 15 minutes, two-way ANOVA was performed to eval-
uate the significant difference among three doses of 
muscimol in this time. P <0.05 was defined as the signif-
icance level. 
Results: 
Muscimol administration causes to reduce the symp-
toms of neuropathic pain, noticeably. As shown in Table 
1, thermal hyperalgesia, mechanical hyperalgesia, cold 
allodynia, and mechanical allodynia decreased after 15 
minutes. Except thermal hyperalgesia (df: 24, 5; F=1.1; 
p=0.12), other neuropathic pain symptoms had signifi-
cant improvement after one hour and three hours of 
muscimol administration.  
Using muscimol with the dose of 0.01 µg/kg in 15 
minutes caused to improve the thermal hyperalgesia 
(df: 24, 5; F= 6.6; p<0.001), mechanical hyperalgesia 
(df: 24, 5; F= 7.8; p<0.001), cold allodynia (df: 24, 5; F= 
6.96; p<0.001), and mechanical allodynia (df: 24, 5; F= 
15.7; p<0.001). Muscimol with a dose of 0.1 µg/kg also 
led to improve the thermal hyperalgesia (df: 24, 5; F= -
5.9; p<0.001), mechanical hyperalgesia (df: 24, 5; F= -
7.2; p<0.001), cold allodynia (df: 24, 5; F= -7.03; 
p<0.001), and mechanical allodynia (df: 24, 5; F= -13.4; 
p<0.001) after 15 minutes of administration. The signif-
icant effect was also seen with a dose of 1 µg/kg (Figure 
1). The analysis of covariance showed that the efficien-
cy of various muscimol doses was similar in reducing 
the symptoms of pain in different times. Based on this 
result, the efficacy of different doses of muscimol did 
not have difference on thermal hyperalgesia (df: 24, 5; 
F= 1.52; p= 0.24), mechanical hyperalgesia (df: 24, 5; F= 
0.3; p= -0.75), cold allodynia (df: 24, 5; F= 0.8; p= -0.56), 
and mechanical allodynia (df: 24, 5; F= 1.75; p= 0.86) 
(Figure 2). 
Discussion: 
The findings of the present study showed that using 
muscimol in each of three evaluated doses leads to re-
duce the acute neuropathic pain. Peak alleviating effect, 
was observed within 15 minutes and gradually de-
creases in three hours. However, except heat hyperal-
gesia, intrathecal administration of muscimol could re-
markably relief the other symptoms. This effect has 
persisted until three hours after administration. It 
Table 1: Effectiveness of muscimol prescrition on neuropatic pains in different times  
Type of test Before administration After 15 minutes The first hour 
The third 
hour 
Thermal hyperalgesia (second)    
0.01µg 10.4 (0.12) 12.8 (0.4)* 10.2 (0.4) 10.1 (0.4) 
0.1µg 10.5 (0.3) 13.04 (0.5)* 9.6 (0.35) 10.4 (0.55) 
1µg 10.2 (0.4) 12.9 (0.8)* 10.1 (0.5) 10.2 (0.4) 
Mechanical hyperalgesia (gram)    
0.01µg 5.2 (0.2) 6.9 (0.2)* 5.8 (0.25)# 5.7 (0.2)# 
0.1µg 5.1 (0.1) 6.6 (0.3)* 5.8 (0.2)# 5.9 (0.1)# 
1µg 5.2 (0.3) 6.8 (0.2)# 5.7 (0.2)* 5.9 (0.1)# 
Cold allodynia (%)     
0.01µg 87.5 (13.9) 52.5 (10.3)# 65.0 (13.9)# 72.5 (5.9) 
0.1µg 97.5 (10.3) 62.5 (7.0)# 68.8 (10.8)# 76.3 (1.8)# 
1µg 96.3 (5.9) 62.5 (11.5)# 71.3 (5.8)# 77.5 (4.9)# 
Mechanical allodynia (gram)    
0.01µg 8.8 (0.55) 14.75 (0.25)* 13.4 (1.1)# 12.2 (1.8)# 
0.1µg 9.3 (0.7) 14.6 (0.3)* 14.3 (0.4)# 13.1 (1.4)# 
1µg 8.5 (0.8) 14.9 (0.1)* 14.4 (0.5)# 13.0 (0.2)# 
*have a significant difference in p<0.001 with before administration time; #shows a significant difference in p<0.05 with before administration 
time. The findings was extracted in terms of repeated measures ANOVA test. 
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should be noted that mechanical allodynia (tactile allo-
dynia) is one of the annoying pain which always SCI 
patients complain of it (25, 26). Therefore, Muscimol 
administration could be able to control mechanical al-
lodynia. Neuropathic pain in human has presented in 
the first days, especially in mechanical allodynia and 
those of SCI which have an incomplete injury (27). Alt-
hough mechanisms responsible for neuropathic pain 
are not fully understood, but it seems that increase in 
glutamate and decrease in GABA content have critical 
role in excitotoxicity, cell death and inflammation, neu-
ronal plasticity and hyperstimulation (28-34). There-
fore, using GABAA agonists like muscimol could reduce 
these pains. The findings obtained in the present study 
confirmed it. Intrathecal administration of medications 
in SCI patients could decrease their systematic effects. 
Consequently, in recent years some methods like in-
trathecal pumps have been used (7, 9, 13). In this re-
gard, the present project was evaluated the effect of 
intrathecal injection of muscimol on pain symptoms in a 
central neuropathic pain model. This method, which 
has favorable outcomes, has been used in controlling 
the acute and chronic pains. However, there are some 
risks aligned with using intrathecal therapy such as 
catheter or pumps dysfunction, catheter removal, caus-
ing inflammatory reactions, and etc (35, 36). Therefore, 
the investigation on this issue is still on. There are just 
few studies, which have evaluated the effect of musci-
mol administration in reducing the neuropathic pain. 
Among these studies, Naik et al. revealed that using 
muscimol in dorsal horn of the spinal cord avoid hyper-
algesia. This animal study used a peripheral injury 
model showed that muscimol causes to improve nerve 
regeneration in addition to decreasing the acute 












 D  C  
Figure 1: Effectiveness of different muscimol dose administration on reducing the neuropatic pain. Data eas peresent as 
Mean±SEM A: heat hyperallgesia; B: mechanical hyperallgesia; C: cold allodynia; D: mechanical allodynia. **have a significant 
difference in p<0.001 with before administration time; *shows a significant difference in p<0.01 with before administration time. 
The significance level was defined in terms of Two-way ANOVA test.  
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hyperalgesia (37). These researchers also displayed in 
another study that muscimol causes to reduce the 
thermal and mechanical hyperalgesia (38). In addition, 
Baba et al showed that using muscimol leads to de-
crease irritability the A and C sensory fibers (39). These 
results support the present findings. Some studies eval-
uated the effectiveness of this drug on chronic models. 
For instance, Miletic et al revealed that muscimol can 
improve the nerve plasticity in posterior horn of the 
spinal cord (40). Such effects aligned with sedative role 
of muscimol, causes to reduce the acute neuropathic 
pain with neuronal growth and synaptic connections, 
too. The outcomes of these changes lead to improve the 
sensory motor function. Finally, it was found that using 
muscimol causes to decrease the neuropathic pain. 
Moreover, the efficiency of this drug progressively re-
duces after 15 minutes for thermal hyperalgesia. As a 
result, it may be possible to use muscimol combined 
with a long-acting drug, endomorphine, or clonidine in 
treatment of neuropathic pains. Of course, more studies 
are needed to determine the efficiency and effective-
ness of this combination therapy. 
Conclusion: 
The finding of the present study revealed that using 
muscimol with doses of 0.01µg, 0.1µg, and 1 µg causes 
to reduce the symptoms of neuropathic pain. Neverthe-
less, its effectiveness gradually decreased after 15 
minutes. Thus, combination therapies could be an ap-
propriate option for compensation of this limitation. 
However, further studies are required to confirm this 
hypothesis. 
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Figure 2: Effectiveness of various muscimol doses on reducing the neuropatic pain symptoms in corresponding times. A: heat 
hyperallgesia; B: mechanical hyperallgesia; C: cold allodynia; D: mechanical allodynia. The significance level was evaluated based 
on ANCOVA test. No significant difference was seen among various doses in evaluated times to reduce the neuropathic pain symp-
toms  
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